OncoC4 begins phase 1/2 Alzheimer's trial dosing
April 10, 2026 | 09:16
The biotechnology company administered its ONC-841 candidate to the initial patient in early-to-mid-stage testing for the neurodegenerative disease.
China fast-tracks Gotistobart as breakthrough cancer drug
October 28, 2025 | 14:53
Anti-CTLA-4 hopeful cleared for sprint to market after early data show rare tumour shrinkage in hard-to-treat patients.
Mobile Version